Found 3 clinical trials
CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children
Adding bortezomid during the consolidation:The very early or early bone marrow relapse has low remission rate. Previous case studies showed that Bortezomib, a proteasome inhibitor, may achieve remission in refractory ALL, 80% remission in B-ALL with combination of chemotherapy and bortezomib. Thus adding bortezomib, may improve the remission rate, thus …
- 0 views
- 16 Feb, 2024
- 1 location
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of VR-CAP (Velcade and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the first-line treatment for patients with marginal zone lymphoma.
- 0 views
- 05 Aug, 2020
Cardiovascular Complications of Carfilzomib
Cardiovascular toxicity of carfilzomib, a last generation proteasome inhibitor, is highly incident according to retrospective data. Prospective cohort study of patients initiated on carfilzomib.
- 0 views
- 05 Aug, 2020